Identification and characterization of the anti-viral interferon lambda 3 as direct target of the Epstein-Barr virus microRNA-BART7-3p

Oncoimmunology. 2023 Nov 27;12(1):2284483. doi: 10.1080/2162402X.2023.2284483. eCollection 2023.

Abstract

The human Epstein-Barr virus (EBV), as a member of the human γ herpes viruses (HHV), is known to be linked with distinct tumor types. It is a double-stranded DNA virus and its genome encodes among others for 48 different microRNAs (miRs). Current research demonstrated a strong involvement of certain EBV-miRs in molecular immune evasion mechanisms of infected cells by, e.g., the disruption of human leukocyte antigen (HLA) class Ia and NKG2D functions. To determine novel targets of EBV-miRs involved in immune surveillance, ebv-miR-BART7-3p, an EBV-encoded miR with high expression levels during the different lytic and latent EBV life cycle phases, was overexpressed in human HEK293T cells. Using a cDNA microarray-based comparative analysis, 234 (229 downregulated and 5 upregulated) deregulated human transcripts were identified in ebv-miR-BART7-3p transfectants, which were mainly involved in cellular processes and molecular binding. A statistically significant downregulation of the anti-proliferative and tumor-suppressive hsa-miR-34A and the anti-viral interferon lambda (IFNL)3 mRNA was found. The ebv-miR-BART7-3p-mediated downregulation of IFNL3 expression was due to a direct interaction with the IFNL3 3'-untranslated region (UTR) as determined by luciferase reporter gene assays including the identification of the accurate ebv-miR-BART7-3p binding site. The effect of ebv-miR-BART7-3p on the IFNL3 expression was validated both in human cell lines in vitro and in human tissue specimen with known EBV status. These results expand the current knowledge of EBV-encoded miRs and their role in immune evasion, pathogenesis and malignant transformation.

Keywords: EBV; EBV target genes; IFNL3; immune escape; microRNA.

MeSH terms

  • Antiviral Agents
  • Epstein-Barr Virus Infections* / genetics
  • Epstein-Barr Virus Infections* / pathology
  • HEK293 Cells
  • Herpesvirus 4, Human / genetics
  • Herpesvirus 4, Human / metabolism
  • Humans
  • Interferon Lambda
  • MicroRNAs* / genetics
  • Nasopharyngeal Neoplasms* / genetics
  • Nasopharyngeal Neoplasms* / metabolism
  • Nasopharyngeal Neoplasms* / pathology

Substances

  • MicroRNAs
  • Interferon Lambda
  • Antiviral Agents

Grants and funding

This article was supported by grants from the German Research Foundation (DFG; project numbers: 496182670 SJB; SE581/34-1 BS), the Jackstädt Foundation (SJB), the Monika Kutzner Foundation (SJB), the German Israelian Foundation (GIF I-1412-414.13-2017; BS, OM) and the BMBF (ZB 031B0800B CW, BS). Funded by the Brandenburg Medical School publication fund supported by the Ministry of Science, Research and Cultural Affairs of the State of Brandenburg.